Compare CASS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | STTK |
|---|---|---|
| Founded | 1906 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.8M | 538.3M |
| IPO Year | 1996 | 2020 |
| Metric | CASS | STTK |
|---|---|---|
| Price | $46.41 | $6.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $45.00 | $10.00 |
| AVG Volume (30 Days) | 54.5K | ★ 539.5K |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 87.77 | 53.02 |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $190,750,000.00 | $1,000,000.00 |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $69.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.07 | $0.71 |
| 52 Week High | $52.45 | $8.33 |
| Indicator | CASS | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 45.12 |
| Support Level | $45.20 | $5.81 |
| Resistance Level | $47.93 | $6.81 |
| Average True Range (ATR) | 1.11 | 0.44 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 53.26 | 32.48 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.